Healthcare is adopting new technologies at an ever increasing pace as organizations map new strategies to integrate cutting-edge technologies into their operations and products. We believe the next decade will be pivotal in the future of healthcare as these new defining technologies continue to emerge.
In recent years, digital health and technology-enabled services sparked a revolution in traditional healthcare delivery models, resulting in an increase in healthcare accessibility, affordability, and efficiency.
Going forward, new cutting-edge technologies ("deep tech") are fueling innovation throughout the healthcare landscape. We believe some of the most promising areas for growth and investment include artificial intelligence (AI)-driven diagnostics, health tech infrastructure, digital therapeutics, and remote patient monitoring.
The groundbreaking impact of AI and machine learning in advancing healthcare diagnostics is truly remarkable. Through AI-powered algorithms, medical imaging like MRI and CT scans are now able to provide more precise and timely disease detection, resulting in earlier interventions and improved outcomes.
AI-powered predictive analytics are empowering healthcare professionals to pinpoint individuals with a heightened likelihood of developing chronic conditions, paving the way for tailored preventive measures.
These examples are just the beginning of an emerging era where data is being harnessed well beyond our expectations. We are more excited than ever to back and nurture top founders who've built cutting-edge technologies in these and other growth areas. Together we are driving important and significant changes that will benefit us all.
Capita3 Fund Updates
Capita3 Partners with Medical Alley
Capita3 and Medical Alley® announced a new strategic partnership to accelerate innovation and investment within its global investor and corporate partner network.
Through this agreement, Medical Alley Starts® — a venture platform which accelerates the formation and growth of healthcare startups — will work with Capita3 to increase technology commercialization, startup launch opportunities, and financing of startups led by women healthcare experts. “Our partnership with Capita3 underscores a shared commitment to shape the next generation of healthcare leaders,” Medical Alley President and CEO Roberta Dressen said. “Through this collaboration, we’ll expand our resources for deep tech startups developing innovations that are central to advancing a sustainable future of health.”
Capita3 Named To Top Female Funds Lists
Excited to be named to the 60 Top Women-led Venture Capital Firms
In 2024 we continue expanding our brand awareness and network of healthcare experts, syndication partners, and institutional investors through speaking engagements and events.
Highlights include: attendance at the Women’s Private Equity Summit, Healthcare.MN, Medical Alley Women in Health Leadership Breakfast, Medical Alley Annual Dinner with Brooke Shields, Women’s Health Leadership Trust Annual Dinner, Invest Midwest VC Forum, MedCity Invest Conference, MidAmerica Healthcare Investor Network Dinner, MATTER 51 Labs Maternal Health Demo Day, DC Finance Chicago Family Office Conference, Recast Capital Annual Summit, the Sutton Capital Allocator Summit and the MedTech MVP Annual Conference.
Upcoming events where you can find us:
LP & Emerging Manager Summit by IIE.VC and the Nasdaq Entrepreneurial Center, San Francisco
June 20
We will attend IIE.VC's event for GP and LP networking.
MedTech MVP Conference, Minneapolis
June 17-18
Capita3 partner Kathy Tune will be speaking on the panel "Forecasting the Future: Leveraging Lessons from the Most Experienced Minds in Medical Device to Create a Viable Future.”
We will be networking with our healthcare venture capital colleagues. Thanks to Wilson Sonsini for their sponsorship!
Private Equity Chicago Forum, Chicago
July 30
The forum brings together investors, funds, and advisers to discuss sectors, due diligence, and private equity investment opportunities in the US and around the world.
Fund II and IIA Portfolio News
Fund II & IIA Investment in Claros
Capita3 Funds II and IIA have invested in Claros Technologies, Inc. This is the second investment in Fund II and the first for Fund IIA. Claros Technologies is commercializing novel technology for the destruction of "forever chemicals", or persistent and harmful chemicals in surface and groundwater. Specifically, Claros is addressing PFAS chemicals, which are used broadly in manufacturing and are linked to a wide range of health risks in humans and animals. PFAS chemicals build up in our bodies and never break down in the environment. Claros is working with global chemical companies to eliminate PFAS chemicals from manufacturing effluent that does or could enter surface or groundwater sources.
The Company was co-founded by CEO Michelle Bellanca, a former executive at 3M where she was the Global Business Director and Managing Director of Strategic Ventures in Asia Pacific. She has deftly navigated the company from its early research days as a spinout company from the University of Minnesota to revenue generation and ready for scale-up.
Fund II Investment in Zerigo
We are excited to share with you our most recent Fund II investment in Zerigo Health. We invested $250K as a part of a $10.9M Convertible Note round, which closed in June 2024. Capita3 was the only outside investor in this round, on invitation by the Company and its Board with anchor investors including 7Wire (Livongo, acquired $13B), HIG Bioventures, and Cigna Ventures.
The company is led by CEO, Lisa Rometty, who joined the Company in August of 2023 as a part of a commercial turnaround. Lisa comes to the company with deep healthcare experience including President of CVS Kidney Care at CVS Health, President of Global Solutions, Syneos Health, VP at IBM Watson and various roles at Baxter International.
Zerigo Health offers an at-home UV light therapy solution (phototherapy) for the treatment of chronic skin conditions such as psoriasis, eczema, and vitiligo. These conditions are commonly treated with expensive drugs and biologic products, which can have significant side effects and don’t work well for many patients. Biologic treatments range from $10,000 to $30,000 on average per patient per year. Since these chronic conditions are often treated over many years, the annual and accumulated costs are significant. As such, payors are driving improved treatments and cost management for this patient population, which creates an opportunity for companies like Zerigo.
Fund I Portfolio News
Intellihealth is a Rising Star
Intellihealth announced a $12M Series A round (at a valuation step up) in 2023 to ramp up their growth. In 2023 the Company also executed a large partnership agreement with Wondr Health and have been integrating their platforms to create a combined solution, Wondr Advanced, and launched to Wondr Health’s 800+ employer customers and 90+ payers. Intellihealth also signed an agreement with the State of Connecticut to be the sole providers for prescribing the new GLP1 medications to their 240K employee population, and launched a partnership with Medifast in New York and New Jersey. The Company was chosen as a Rising Star under the prestigious Digital Health Hub Foundation.
B.well's Leadership is Undeniable
B.well continues to lead - The recent B.well publication "Going Beyond the Digital Front Door to Unlock Precision Healthcare Through Data and Ecosystem Unification" highlights the need to move beyond simply offering digital point solutions to full fledged longitudinal views of a person's health. This is the only way to turn data into actionable information and insights and enable both patients and their caregivers. B.well leads the market in this important enabling technology for the healthcare marketplace. Partnerships with Clear, Samsung, Walgreens, among many others continue to validate the need and B.well's compelling offering.
